Alphabet’s Isomorphic Labs raises $600M in first funding round for AI drug business
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, the AI drug discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...
Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Google DeepMind’s drug discovery spin-off Isomorphic Labs raises $600mn
Isomorphic Labs, the drug discovery start-up spun out of Google’s DeepMind artificial intelligence unit, has raised $600mn in its first external funding round, as investors bet on the potential for AI ...
pharmaphorum3d
Novartis launches digital health innovation lab the Novartis Biome
The Novartis Biome, whose first digital health innovation lab is based in San Francisco, has been co-founded by its head Mohanad Fors, head of open innovation Shwen Gwee and head of innovation and ...
pharmaphorum1d
Novartis taps Microsoft’s AI expertise for drug development
The five-year deal to create a joint AI Innovation Lab, which will be reviewed every year, will initially focus on applying AI across Novartis’ internal processes. The aim is to create a data ...
Novartis11d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...
FiercePharma3d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...
MediaPost27d
From Jogging To 'Things That Really Matter': Novartis Transforms Its Content
“We have an opportunity to break through by looking different than other brands in our space,” said Marti, who works with Novartis’ three-year-old Content Lab. “We do that by thinking ...